These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37171344)

  • 1. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
    Hu X; Li D; Wang R; Wang P; Cai J
    Medicine (Baltimore); 2023 May; 102(19):e33726. PubMed ID: 37171344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
    Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
    Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
    Xu S; Pan Y; Zhou J; Ju H; Zhang Y
    Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors.
    Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S
    Neuroendocrinology; 2024; 114(8):775-785. PubMed ID: 38824926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
    Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
    Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of
    Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Findings in a Patient With Primary Renal Well-Differentiated Neuroendocrine Tumor.
    Şahin R; Baykal Koca S; Yücetaş U; Çermik TF; Ergül N
    Clin Nucl Med; 2022 Jul; 47(7):e503-e505. PubMed ID: 35384913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
    Hindié E
    Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of
    Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
    Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.
    Ryzhkova D; Mitrofanova L; Tsoy U; Grineva E; Schlyakhto E
    Front Endocrinol (Lausanne); 2022; 13():958442. PubMed ID: 36133304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.